Hair loss

DHT and Hair Loss: A Plain-Language Explanation

Save

DHT (dihydrotestosterone) is a hormone derived from testosterone that drives most pattern hair loss. In people who are genetically susceptible, DHT gradually shrinks certain scalp follicles until they can no longer produce visible hair. This process is well understood, and several treatments work by reducing DHT's effect on follicles — understanding the mechanism helps you have a much more informed conversation with a clinician about options.

Last updated: July 2026History

Talk to a clinician

A skin & hair clinician

Gale can help you find one in your state and request a visit.

Find care →

What is DHT and where does it come from?

DHT stands for dihydrotestosterone, an androgen (male-type hormone) present in both men and women. It is made when an enzyme called 5-alpha reductase converts testosterone into DHT, primarily in tissues including the skin, scalp, liver, and prostate. DHT is more potent than testosterone at androgen receptors. In early life it plays an important role in sexual development. In adulthood, elevated sensitivity to DHT in certain scalp follicles is the main driver of androgenetic alopecia — the most common form of progressive hair loss 1.

Why does DHT miniaturize only certain follicles?

Not all follicles respond to DHT equally. In people with a genetic predisposition, follicles at the front, top, and crown of the scalp carry a higher density of androgen receptors and are more sensitive to DHT's effects. Repeated exposure causes these follicles to progressively shrink: the active growth phase (anagen) gets shorter with each hair cycle, the shaft gets finer, and eventually the follicle stops producing a visible hair 12.

Crucially, follicles at the back and sides of the scalp are largely DHT-resistant — which is why the horseshoe pattern of remaining hair is typical in advanced male pattern baldness, and why donor hair from that zone is used in transplants. The pattern is predictable because the sensitivity is encoded genetically, not from anything the person does or does not do.

How does DHT-driven hair loss present in women?

Women also produce DHT, though typically at lower levels than men. Female pattern hair loss more often appears as diffuse thinning across the crown and a widening part rather than a receding hairline 3. The DHT mechanism is the same, though hormonal interactions are more complex — estrogen partly counteracts androgen effects on follicles, which is why hair loss often becomes more noticeable after menopause or in conditions associated with elevated androgens such as polycystic ovary syndrome (PCOS) 4.

Treatments that target the DHT pathway

The two most established medical approaches for pattern hair loss work through this pathway. Finasteride is a 5-alpha reductase inhibitor that reduces DHT production, slowing follicle miniaturization and in some cases promoting partial reversal in miniaturized but viable follicles 5. Dutasteride works similarly but inhibits more forms of the 5-alpha reductase enzyme, producing a greater reduction in DHT. A systematic review and meta-analysis found both finasteride and minoxidil to be effective for androgenetic alopecia compared with placebo 2.

Topical minoxidil works through a different mechanism — it prolongs the active growth phase of follicles, independent of DHT. These medications are not interchangeable, and each carries its own benefit and risk profile. A clinician is best placed to advise whether one is appropriate for you, at what dose, and for how long.

What DHT treatment cannot do

Reducing DHT can slow or halt further miniaturization and, in some cases, partially reverse it in follicles that are suppressed but not yet permanently dormant. It cannot regrow hair from completely gone follicles — which is why earlier treatment generally produces better results.

DHT-targeting treatment will also not address hair loss from other causes. Shedding due to iron deficiency, thyroid disease, or telogen effluvium will not respond to finasteride or dutasteride, which is another reason a proper diagnosis matters before starting any medication 2.

Common questions

Not necessarily. Androgenetic alopecia is polygenic — it is influenced by genes from both parents' sides. A family history increases likelihood but does not guarantee the same outcome. The maternal grandfather's hair is relevant too, despite common belief that only the father's side matters.

Systematic review evidence supports finasteride's effectiveness for slowing hair loss and, in many cases, promoting some regrowth in androgenetic alopecia. Side effects — including changes in sexual function — have been reported in a minority of users and are generally reversible on stopping, though they deserve discussion with a prescribing clinician before starting.

Some DHT-related treatments are used in women, but the approach differs from men — finasteride at the doses used in men is not approved for premenopausal women because of risks in pregnancy. A dermatologist or endocrinologist can discuss options appropriate for women, including topical minoxidil and, in some cases, anti-androgen medications.

Yes — exogenous testosterone and anabolic steroids significantly raise DHT levels and can dramatically accelerate hair loss in those who are genetically susceptible, sometimes irreversibly. This is an important consideration for anyone who is genetically prone to androgenetic alopecia and considering such therapies.

The pattern and progression are the main clues: gradual thinning at the temples, crown, or part with a family history strongly suggests androgenetic alopecia. Sudden, diffuse, or patchy loss — or loss with systemic symptoms — suggests other causes such as telogen effluvium, alopecia areata, thyroid disease, or iron deficiency. A dermatologist can often distinguish these on examination, sometimes with dermoscopy or blood work.

Related

Say it back

How would you explain this to someone you love?

Two or three sentences, just as you’d say it. Gale reflects back what you focused on — a mirror, not a quiz.

Talk to a clinician

A skin & hair clinician

Gale can help you find one in your state and request a visit.

Find care →

When the pattern suggests something else

  • —Sudden or patchy hair loss rather than gradual diffuse thinning — this pattern suggests a different cause, not androgenetic alopecia
  • —Scalp pain, redness, or scarring alongside hair loss
  • —Hair loss outside the classic androgenetic pattern — temples and crown in men; widening part in women
  • —Hair loss with other hormonal symptoms such as irregular periods, acne, or unexpected muscle changes — may indicate elevated androgens requiring evaluation

This article explains general mechanisms and is not a diagnosis or personalized medical advice. Decisions about medication for hair loss should be made with a licensed clinician who can evaluate your individual health history.

Did this answer your question?

References

  1. 1.Mella JM, Perret MC, Manzotti M, Catalano HN, Guyatt G (2010). Efficacy and safety of finasteride therapy for androgenetic alopecia: a systematic review. Archives of Dermatology. doi:10.1001/archdermatol.2010.256 ✓DHT as the driver of androgenetic alopecia and finasteride's mechanism in reducing DHT to slow miniaturization
  2. 2.Adil A, Godwin M (2017). The effectiveness of treatments for androgenetic alopecia: A systematic review and meta-analysis. Journal of the American Academy of Dermatology. doi:10.1016/j.jaad.2017.02.054 ✓Effectiveness of finasteride and minoxidil for androgenetic alopecia; importance of correct diagnosis before treatment
  3. 3.Ioannides D, Lazaridou E (2015). Female pattern hair loss. Current Problems in Dermatology. doi:10.1159/000369404 ✓Female pattern of androgenetic alopecia — diffuse crown thinning and widening part rather than receding hairline; DHT mechanism in women
  4. 4.American College of Obstetricians and Gynecologists (2018). ACOG Practice Bulletin No. 194: Polycystic Ovary Syndrome. Obstetrics & Gynecology. doi:10.1097/AOG.0000000000002656 ✓PCOS and elevated androgens as a driver of hair loss in women; post-menopause estrogen decline unmasking androgenetic alopecia
  5. 5.Mella JM, Perret MC, Manzotti M, Catalano HN, Guyatt G (2010). Efficacy and safety of finasteride therapy for androgenetic alopecia: a systematic review. Archives of Dermatology. doi:10.1001/archdermatol.2010.256 ✓Finasteride's efficacy in slowing and partially reversing follicle miniaturization in androgenetic alopecia

5 sources, numbered by first appearance. General health information, not medical advice. AI-assisted editorial content — every citation independently verified. Editorial policy

← Back to the health library